Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• ThikeAAIqbalJCheokPYTriple negative breast cancer: outcome correlation with immunohistochemical detection of basal markersAm J Surg Pathol201034795696420495445
   PubMed Web of Science ®Google Scholar
• PalmaGFrasciGChiricoATriple negative breast cancer: looking for the missing link between biology and treatmentsOncotarget2015629265602657426387133
   PubMedGoogle Scholar
• Ismail-KhanRBuiMMA review of triple-negative breast cancerCancer Control201017317317620664514
   PubMed Web of Science ®Google Scholar
• PratAAdamoBCheangMCAndersCKCareyLAPerouCMMolecular characterization of basal-like and non-basal-like triple-negative breast cancerOncologist201318212313323404817
   PubMed Web of Science ®Google Scholar
• ZhouLLiKLuoYNovel prognostic markers for patients with triple-negative breast cancerHum Pathol201344102180218723845466
   PubMedGoogle Scholar
• RodyAKarnTRuckhäberleEGene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancerBreast Cancer Res Treat2009113345746618340528
   PubMedGoogle Scholar
• TeweyKMRoweTCYangLHalliganBDLiuLFAdriamycin-induced DNA damage mediated by mammalian DNA topoisomerase IIScience198422646734664686093249
   PubMed Web of Science ®Google Scholar
• HarrisLNBroadwaterGAbu-KhalafMTopoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013J Clin Oncol200927213430343619470942
   PubMedGoogle Scholar
• ManoMSRosaDDDe AzambujaEIsmaelGFDurbecqVThe 17q12-q21 amplicon: her2 and topoisomerase-IIalpha and their importance to the biology of solid tumoursCancer Treat Rev2007331647717113234
   PubMedGoogle Scholar
• OlszewskiWPieńkowskiTOlszewskiWTopoisomerase 2α status in invasive breast carcinoma – comparison of its clinical value according to immunohistochemical and fluorescence in situ hybridization methods of evaluationPol J Pathol201465428329025693082
   PubMedGoogle Scholar
• RomeroAMartínMCheangMCAssessment of Topoisomerase II |á status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridizationAm J Pathol201117841453146021435434
   PubMedGoogle Scholar
• SparanoJAGoldsteinLJChildsBHRelationship between topoi-somerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancerClin Cancer Res200915247693770019996222
   PubMedGoogle Scholar
• DiLADesmedtCBartlettJMHER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient dataLancet Oncol201112121134114221917518
   PubMedGoogle Scholar
• O’MalleyFPChiaSTuDTopoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapyJ Natl Cancer Inst2009101964465019401546
   PubMedGoogle Scholar
• MichaletXPinaudFFBentolilaLAQuantum dots for live cells, in vivo imaging, and diagnosticsScience2005307570953854415681376
   PubMed Web of Science ®Google Scholar
• WangYChenLQuantum dots, lighting up the research and development of nanomedicineNanomedicine20117438540221215327
   PubMed Web of Science ®Google Scholar
• WangXYangLChenZGShinDMApplication of nanotechnology in cancer therapy and imagingCA Cancer J Clin20085829711018227410
   PubMed Web of Science ®Google Scholar
• ChenCPengJSunSRPengCWLiYPangDWTapping the potential of quantum dots for personalized oncology: current status and future perspectivesNanomedicine (Lond)20127341142822385199
   PubMed Web of Science ®Google Scholar
• WangLWPengCWChenCLiYQuantum dots-based tissue and in vivo imaging in breast cancer researches: current status and future perspectivesBreast Cancer Res Treat2015151171725833213
   PubMedGoogle Scholar
• YuanJPWangLWQuAPQuantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancerPLoS One2015104e012273425856425
   PubMed Web of Science ®Google Scholar
• SunJZChenCJiangGTianWQLiYSunSRQuantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancerInt J Nanomedicine201491339134624648732
   PubMed Web of Science ®Google Scholar
• ChenCYuanJPWeiWSubtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indicationsInt J Nanomedicine201491039104824591826
   PubMed Web of Science ®Google Scholar
• ZhengHMChenCWuXHQuantum dot-based in situ simultaneous molecular imaging and quantitative analysis of EGFR and collagen IV and identification of their prognostic value in triple-negative breast cancerTumour Biol20163722509251826385773
   PubMedGoogle Scholar
• QiaoJHJiaoDCLuZDYangSLiuZZClinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancerTumour Biol20153696833683825846735
   PubMedGoogle Scholar
• KarnesRJChevilleJCIdaCMThe ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG statusCancer Res201070228994900221062978
   PubMedGoogle Scholar
• MoiseyenkoVMVolkovNMSuspistinENEvidence for predictive role of BRCA1 and bTUBIII in gastric cancerMed Oncol201330254523532817
   PubMedGoogle Scholar
• Sherman-BaustCAKuhnEValleBLA genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma developmentJ Pathol2014233322823724652535
   PubMedGoogle Scholar
• RomeroACaldésTDíaz-RubioEMartínMTopoisomerase 2 alpha: a real predictor of anthracycline efficacyClin Transl Oncol201214316316822374418
   PubMedGoogle Scholar
• García-CaballeroTPrietoOVázquez-BoqueteADual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomasBreast Cancer Res Treat20141431818924292870
   PubMedGoogle Scholar
• JacotWFicheMZamanKWolferALamyPJThe HER2 amplicon in breast cancer: topoisomerase IIA and beyondBiochim Biophys Acta20131836114615723628726
   PubMedGoogle Scholar
• ReinholzMMBruzekAKVisscherDWBreast cancer and aneusomy 17: implications for carcinogenesis and therapeutic responseLancet Oncol200910326727719261255
   PubMedGoogle Scholar
• FountzilasGValavanisCKotoulaVHER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapyJ Transl Med2012101022240029
   PubMed Web of Science ®Google Scholar
• BraseJCSchmidtMFischbachTERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and predictionClin Cancer Res20101682391240120371687
   PubMed Web of Science ®Google Scholar
• ChenCPengJXiaHQuantum-dot-based immunofluorescent imaging of HER2 and ER provides new insights into breast cancer heterogeneityNanotechnology201021909510120110584
   PubMed Web of Science ®Google Scholar
• ChenCPengJXiaHSQuantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancerBiomaterials200930152912291819251316
   PubMed Web of Science ®Google Scholar
• FountzilasGChristodoulouCBobosMTopoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumabJ Transl Med20121021223092535
   PubMedGoogle Scholar
• PressMFSauterGBuyseMAlteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapyJ Clin Oncol201129785986721189395
   PubMed Web of Science ®Google Scholar
• TurleyHComleyMHoulbrookSThe distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissuesBr J Cancer1997759134013469155056
   PubMed Web of Science ®Google Scholar
• GradisharWJAndersonBOBalassanianRBreast cancer, version 1. 2016J Natl Compr Canc Netw201513121475148526656517
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar